Consensus on the clinical diagnosis and treatment of grade 3 pancreatic neuroendocrine tumors

Author:

Chen Jie1,Wu Wenming2,Bai Chunmei3,Chi Yihebali4,Huo Li5,Jiang Liming6,Ji Yuan7,Luo Jie8,Li Jie9,Li Jingnan10,Lou Wenhui11,Shao Chenghao12,Shen Lin13,Wang Feng14,Wang Yu15,Xue Ling16,Xu Jin17,Yuan Chunhui18,Yu Xianjun17,Yin Xiaoyu19,Zhao Hong20,Zhu Xiongzeng21,Zhao Yupei2

Affiliation:

1. Centre for Neuroendocrine Tumors, Fudan University Shanghai Cancer Center, Shanghai 200032, China

2. Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China

3. Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China

4. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

5. Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China

6. Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

7. Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

8. Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China

9. Department of Gastroenterological Oncology, Beijing Cancer Hospital, Peking University Cancer Hospital & Institute, Beijing 100142, China

10. Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China

11. Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China

12. Department of Pancreatic-Biliary Surgery, Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China

13. Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China

14. Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China

15. Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China

16. Department of Pathology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen 518107, China

17. Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Pancreatic Cancer Institute Fudan University, Shanghai Pancreatic Cancer Institute, Shanghai 200032, China

18. Department of General Surgery, Peking University Third Hospital, Beijing 100191, China

19. Department of Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China

20. Department of Hepatobiliary Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China

21. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Abstract

The World Health Organization (WHO) 2017 classifications for neuroendocrine neoplasms (NENs) subdivided grade 3 pancreatic neuroendocrine neoplasms (pNENs) into G3 well-differentiated pancreatic neuroendocrine tumors (G3 pNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (pNECs), according to the mitotic count, Ki-67 index, and cell differentiation. As a new category, G3 pNETs remain a challenging group of tumors to manage by lacking large randomized trials and consensus to support its clinical practice. Therefore, the Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association gathered experts in this field to formulate this consensus for the diagnosis and treatment of G3 pNETs.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3